How Doctors Use Blood Tests to Distinguish Benign From Malignant Conditions
The Laboratory’s Role in One of Medicine’s Most Important Distinctions
When a patient in Lahore presents with an unexplained lump, persistent weight loss, chronic fatigue, or an abnormal finding on imaging, the question that follows every clinical assessment is the same — is this benign or malignant? It is the distinction that determines everything — the urgency of further investigation, the treatment pathway, the prognosis, and the emotional weight the patient and their family must carry while answers are sought.
Blood tests cannot always provide a definitive answer to this question on their own. Tissue biopsy remains the gold standard for confirming malignancy in most clinical contexts. But blood tests contribute enormously to the diagnostic process — narrowing the differential, raising or lowering suspicion, guiding the urgency of further investigation, and in some cases providing strong independent evidence of malignancy before any tissue is sampled. At Alnoor Diagnostic Centre in Shadman, Lahore, our laboratory provides the comprehensive haematological and biochemical investigations that support clinicians across the city in making these critical distinctions.
The Complete Blood Count — The First and Most Fundamental Screen
The complete blood count is frequently the first investigation to suggest that something more serious than a benign condition may be present. Several characteristic patterns in the CBC raise immediate concern for malignancy.
A markedly elevated white cell count — particularly when the differential shows a predominance of immature or abnormal white cells — raises immediate concern for leukaemia. Chronic lymphocytic leukaemia — the most common adult leukaemia — characteristically presents with a persistently elevated lymphocyte count that may be discovered incidentally on a routine blood test in an otherwise well patient. Chronic myeloid leukaemia produces a markedly elevated total white count with a characteristic left shift — increased proportions of immature myeloid cells at various stages of development. Acute leukaemias present more dramatically with very high or very low white counts, anaemia, and severe thrombocytopaenia from bone marrow failure.
Anaemia in the absence of an obvious benign explanation — without iron deficiency, without B12 or folate deficiency, without chronic inflammatory disease — prompts investigation for occult malignancy. Chronic blood loss from a colorectal tumour produces iron deficiency anaemia that may precede any gastrointestinal symptoms by months. Bone marrow infiltration by metastatic solid tumours produces a characteristic leukoerythroblastic blood picture — immature red and white cells appearing in the circulation — that signals marrow involvement even before imaging identifies the primary tumour.
Thrombocytopaenia unexplained by medication or viral illness can indicate bone marrow infiltration or peripheral platelet destruction associated with malignancy. Conversely, marked thrombocytosis — elevated platelet count — in the context of unexplained anaemia may indicate an underlying solid tumour producing reactive thrombocytosis.
Tumour Markers — Biochemical Signals of Malignant Activity
Tumour markers are proteins, hormones, or other molecules produced by cancer cells — or produced by normal cells in response to cancer — that can be measured in the blood. Their clinical role is frequently misunderstood. Most tumour markers are not sufficiently sensitive or specific to diagnose cancer reliably on their own — an elevated marker does not confirm malignancy and a normal marker does not exclude it. Their real value lies in supporting diagnosis when interpreted alongside clinical findings and imaging, and in monitoring known malignancy for treatment response and recurrence.
Prostate-specific antigen — PSA — is the most widely used tumour marker in clinical practice. Elevated PSA raises suspicion for prostate cancer but also occurs in benign prostatic hypertrophy, prostatitis, and after urological instrumentation. The rate of PSA rise over time — PSA velocity — and the ratio of free to total PSA provide additional discrimination between benign and malignant causes of elevation. PSA is most valuable as a monitoring tool in known prostate cancer — a rising PSA after treatment signals recurrence before imaging demonstrates it.
CA-125 is elevated in ovarian cancer but also rises in endometriosis, pelvic inflammatory disease, liver disease, and other benign conditions. Its primary clinical use is in monitoring response to treatment in confirmed ovarian cancer and detecting recurrence, rather than as a diagnostic screening test. When CA-125 is markedly elevated — particularly in a postmenopausal woman with a pelvic mass — the combination substantially raises the probability of malignancy and directs urgent further investigation.
CEA — carcinoembryonic antigen — is elevated in colorectal cancer, lung cancer, gastric cancer, and breast cancer, but also in smokers and patients with inflammatory bowel disease and liver disease. A markedly elevated CEA in the context of unexplained weight loss, change in bowel habit, or a suspicious mass is clinically significant and warrants urgent colonoscopy and imaging. Its greatest utility is in monitoring colorectal cancer after resection — a rising CEA is the first signal of recurrence in many patients.
AFP — alpha-fetoprotein — is markedly elevated in hepatocellular carcinoma and certain testicular germ cell tumours. In Pakistan, where hepatitis B and C-related liver cirrhosis is common, AFP monitoring in cirrhotic patients forms part of hepatocellular carcinoma surveillance. A markedly elevated AFP in a cirrhotic patient with a hepatic mass is highly suggestive of hepatocellular carcinoma and triggers urgent management decisions.
Beta-hCG is elevated in choriocarcinoma and testicular germ cell tumours and is used both diagnostically and as a monitoring marker. LDH — lactate dehydrogenase — is a non-specific marker of cell turnover elevated in many malignancies including lymphoma, leukaemia, and metastatic cancer, and its level carries prognostic significance in several cancer types.
Protein Electrophoresis — Identifying Plasma Cell Malignancies
Serum protein electrophoresis is the investigation that identifies multiple myeloma and related plasma cell disorders. It separates serum proteins by their electrical charge, producing a characteristic pattern. In multiple myeloma, malignant plasma cells produce a large amount of a single abnormal immunoglobulin — a paraprotein or M-protein — that appears as a sharp, narrow spike in the gamma globulin region of the electrophoresis pattern. This monoclonal spike is highly characteristic of plasma cell malignancy and is not produced by benign conditions.
Multiple myeloma is a condition frequently diagnosed late in Pakistan because its presenting features — bone pain, anaemia, recurrent infections, and renal impairment — are common to many benign conditions. Protein electrophoresis is a relatively simple and affordable investigation that identifies the diagnostic abnormality directly, and its wider use would undoubtedly result in earlier diagnosis and better outcomes for myeloma patients in Lahore.
Inflammatory Markers — Useful But Non-Specific
Inflammatory markers — ESR, CRP, ferritin, and LDH — are elevated in both malignant and benign inflammatory conditions, limiting their diagnostic specificity. However, markedly elevated values out of proportion to any identifiable benign cause raise suspicion for malignancy. A markedly elevated ferritin — particularly values many times above the upper limit of normal — occurs in haematological malignancies, lymphoma, and systemic malignancy with hepatic involvement. An ESR persistently above 100 millimetres per hour without explanation warrants investigation for myeloma, lymphoma, and solid malignancy alongside benign inflammatory causes.
Integrated Interpretation — The Clinician’s Role
No blood test in isolation confirms or excludes malignancy. The skill lies in interpreting the complete pattern of blood test results alongside the clinical presentation, imaging findings, and risk factors — recognising combinations that together substantially raise or lower the probability of malignancy and direct the next investigation efficiently. A mildly elevated PSA in isolation means little. A mildly elevated PSA in a sixty-year-old man with lower urinary tract symptoms, a hard irregular prostate on examination, and an elevated alkaline phosphatase suggesting bone involvement means a great deal more.
Laboratory Services at Alnoor Diagnostic Centre, Lahore
At Alnoor Diagnostic Centre in Shadman, Lahore, our laboratory provides the complete range of haematological, biochemical, and tumour marker investigations that clinicians across the city depend on for accurate diagnostic assessment. Our experienced laboratory team delivers results with the precision and turnaround that time-sensitive clinical decisions demand.